rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    MXCT
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Stifel reiterates Buy on MaxCyte stock, cites Q3 growth momentum
      Nov 12Investing.comMXCTSF
      MaxCyte, Inc. Q3 2026 Earnings Call Summary
      Nov 11Yahoo FinanceMXCT
      MaxCyte Inc (MXCT) (Q3 2026) Earnings Call Highlights: Revenue Surges 49% as Accron Acquisition ...
      Nov 11Yahoo FinanceMXCT
      MaxCyte Q3 2026 Earnings Call Transcript
      Nov 10BenzingaMXCT
      MaxCyte Q3 Earnings Call Highlights
      Nov 10Yahoo FinanceMXCT
      MaxCyte stock dips on deal to buy Akron Bio (MXCT:NASDAQ)

      MaxCyte (MXCT) stock dips as the company agrees to buy Akron BioProducts for $151.8M in cash and stock. Read more here.

      Nov 10Seeking AlphaMXCT
      MaxCyte to Acquire Akron Bio, Expanding its Offerings Across Cell Therapy Manufacturing and Expecting to Nearly Double Revenue Base
      Nov 10Yahoo FinanceMXCT
      12 Health Care Stocks Moving In Monday's Pre-Market Session
      Nov 9BenzingaMXCTVIR
      12 Health Care Stocks Moving In Wednesday's Intraday Session - MaxCyte (NASDAQ:MXCT), Liquidia (NASDAQ:LQ

      Gainers MaxCyte (NASDAQ:MXCT) shares rose 34.5% to $1.3 during Wednesday's regular session. The company's market cap stands at $102.6 million. Liquidia (NASDAQ:LQDA) stock moved upwards by 26.29% to $33.86.

      Oct 14BenzingaLQDAMXCT
      MaxCyte stock surges 25% on raised 2026 revenue guidance
      Oct 14Investing.comMXCT
      MaxCyte raises 2026 revenue guidance on strong Q3 results
      Oct 14Investing.comMXCT
      MaxCyte appoints Sidharth Kapileshwar as chief corporate officer
      Sep 23Investing.comMXCT
      Analysts Have Conflicting Sentiments on These Healthcare Companies: Lexicon Pharmaceuticals (LXRX) and MaxCyte (MXCT)

      Detailed price information for Maxcyte Inc (MXCT-Q) from The Globe and Mail including charting and trades.

      Aug 25The Globe and MailLXRXMXCT
      MaxCyte stock rating held at Neutral by BTIG after Q2 results
      Aug 24Investing.comMXCT

      This is the newest page. Registered accounts read further back.